Home > News > Biopharmaceutical Midday Gainers: QGLY, BPAX, NXXI - sourced PicksThatMove.com
August 18th, 2009
Biopharmaceutical Midday Gainers: QGLY, BPAX, NXXI - sourced PicksThatMove.com
Abstract:
Biosante Pharmaceuticals, Inc. (NGM: BPAX) maintained its gain of 15.82% by midday to rise to $2.27 (the company was up 25% in pre-trading) on news clinical trials show that it's booster adjuvant bio-enhances and increases the efficacy of vaccines, including new vaccines for H1N1. Based in Lincolnshire, Illinois, Biosante Pharmaceuticals is a biopharmaceutical company developing hormone therapy products to treat men and women. It also develops proprietary nanotechnology. The company also produces aesthetic derma filers, BioVant for the treatment of viral and bacterial infections and autoimmune diseases, as well as inhalable applications for protein and therapy administration.
Source:
transworldnews.com
Bookmark:
| Related Links |
| Related News Press |
News and information
Researchers develop molecular qubits that communicate at telecom frequencies October 3rd, 2025
Next-generation quantum communication October 3rd, 2025
"Nanoreactor" cage uses visible light for catalytic and ultra-selective cross-cycloadditions October 3rd, 2025
Nanomedicine
New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes August 8th, 2025
New imaging approach transforms study of bacterial biofilms August 8th, 2025
Cambridge chemists discover simple way to build bigger molecules – one carbon at a time June 6th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Announcements
Rice membrane extracts lithium from brines with greater speed, less waste October 3rd, 2025
Researchers develop molecular qubits that communicate at telecom frequencies October 3rd, 2025
Next-generation quantum communication October 3rd, 2025
"Nanoreactor" cage uses visible light for catalytic and ultra-selective cross-cycloadditions October 3rd, 2025
Financial Reports
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
Nanobiotechnology
New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes August 8th, 2025
New imaging approach transforms study of bacterial biofilms August 8th, 2025
Ben-Gurion University of the Negev researchers several steps closer to harnessing patient's own T-cells to fight off cancer June 6th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||